|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.35 USD | +11.97% |
|
+19.79% | +84.30% |
| 07/05 | Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial | RE |
| 06/05 | Novavax beats first-quarter revenue estimates on strength in vaccine deals | RE |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 19 | |||||||
| 28 | |||||||
| 19 | |||||||
| 25 | |||||||
| 16 | |||||||
| 29 | |||||||
| 27 | |||||||
| 22 | |||||||
| 13 | |||||||
| 23 | |||||||
| 4 | |||||||
| 21 | |||||||
| 24 | |||||||
| 9 | |||||||
| - | 1 | ||||||
| 11 | |||||||
| 12 | |||||||
| - | 1 | ||||||
| - | - | ||||||
| Average | 17 | |||||||
| Weighted average by Cap. | 21 |
- Stock Market
- Equities
- MRNA Stock
- Sector Moderna, Inc.
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition